ArticleSurgical endoscopy2009
Endoscopic endoluminal radiofrequency ablation of Barrett's esophagus: initial results and lessons learned.
Article in Surgical endoscopy, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 4 syntheses or guidelines pooled it, 48 citations in OpenAlex.
- Efficacy and durability of radiofrequency ablation for Barrett's Esophagus: systematic review and meta-analysis.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2013Pooled it
- A systematic review of the evidence for radiofrequency ablation for Barrett's esophagus.Surgical endoscopy · 2010Pooled it
- Guidelines for surgical treatment of gastroesophageal reflux disease.Surgical endoscopy · 2010Guideline
- Endoscopic treatments for Barrett's esophagus: a systematic review of safety and effectiveness compared to esophagectomy.BMC gastroenterology · 2010Pooled it
- Outcomes from a prospective trial of endoscopic radiofrequency ablation of early squamous cell neoplasia of the esophagus.Gastrointestinal endoscopy · 2011Trial
- Durability of radiofrequency ablation for long-segment and ultralong-segment Barrett's esophagus over 10 years.Surgical endoscopy · 2024Article
- The cost effectiveness of radiofrequency ablation for Barrett's esophagus.Gastroenterology · 2012Article
- Increased risk for persistent intestinal metaplasia in patients with Barrett's esophagus and uncontrolled reflux exposure before radiofrequency ablation.Gastroenterology · 2012Article
- Endoscopic management of early esophageal neoplasia: an emerging standard.Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract · 2011Article
- Endoscopic resection techniques and ablative therapies for Barrett's neoplasia.World journal of gastrointestinal endoscopy · 2011Article
- Barrett's esophagus: endoscopic treatments II.Annals of the New York Academy of Sciences · 2011Article
- Ablative therapies for Barrett's esophagus.Current gastroenterology reports · 2011Review
- Effects of Nissen fundoplication on endoscopic endoluminal radiofrequency ablation of Barrett's esophagus.Surgical endoscopy · 2011Article
- The case for endoscopic treatment of non-dysplastic and low-grade dysplastic Barrett's esophagus.Digestive diseases and sciences · 2010Review
- Diagnosis and management of Barrett's esophagus for the endoscopist.Therapeutic advances in gastroenterology · 2010Article
- Treatment of ultralong-segment Barrett's using focal and balloon-based radiofrequency ablation.Surgical endoscopy · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAblating Barrett's epithelium may reduce the risk of developing esophageal adenocarcinoma. This study reports the experience of a single surgeon using an endoscopic endoluminal device that delivers radiofrequency energy (the BARRx device) to ablate Barrett's esophagus.
methodsAll patients who underwent ablation of Barrett's epithelium with the BARRx system were reviewed for length of Barrett's metaplasia, presence of high-grade dysplasia, postprocedure complications, completeness of ablation at first follow-up endoscopy, need for additional ablation, completeness of ablation at second follow-up endoscopy, and concomitant performance of a Nissen fundoplication.
resultsSixty-six patients underwent Barrett's ablation. The median length of the Barrett's esophagus was 3 (range, 1-14) cm. Twelve patients (18%) had high-grade dysplasia. There were no immediate procedure-related complications. Four strictures occurred: three in patients with > or = 12-cm segments of Barrett's and one in a 6-cm segment. Twenty-nine of 49 patients (59%) who had planned 3-month follow-up endoscopy had complete ablation. Five patients had planned two-stage ablation. Twenty patients with incomplete ablation had additional ablation. Twenty-seven patients had planned follow-up endoscopy at > or = 1 year: 25 of 27 (93%) had biopsy-proven normal esophageal mucosa. The median length of Barrett's esophagus in patients with initially incomplete ablation was 6 cm, compared with 2 cm in the initially complete ablation patients. Seven Nissen fundoplications were present at the time of ablation, whereas six were performed concomitantly with the ablation without increased difficulty.
conclusionsComplete ablation of Barrett's esophagus with radiofrequency endoluminal ablation is achievable in > 90% of patients. Patients with longer segments are likely to require additional ablation. Patients with very long segments are at risk for stricture and should be approach cautiously. Performance of a fundoplication is not hindered by concomitant ablation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.